In Vivo Base Editing Therapy

Mechanism

Related News

YolTech Therapeutics Receives FDA Clearance for Phase 2/3 Study of YOLT-202 in AATD

Mar 14, 2026

YolTech Therapeutics received FDA approval for its IND application for YOLT-202, an in vivo gene-editing therapy for Alpha-1 Antitrypsin Deficiency. Interim data from an ongoing trial showed rapid increases in AAT levels to normal range with favorable safety.

Biotechnology Market Shifts to Engineering Discipline, Expected to Grow 13-15% Through 2029

Feb 26, 2026

The global biotechnology market is undergoing a transformation from discovery-based science to precision engineering, driven by AI, synthetic biology, and gene editing technologies, with projected growth of 13-15% over the next five years.